Patients across the UK are being urged to check their blood pressure medication after a labeling error led to the recall of a specific batch of Lercanidipine hydrochloride tablets. The Medicines and Healthcare products Regulatory Agency (MHRA) issued the alert following reports that some packs were incorrectly labeled, posing potential health risks.
Details Behind the Blood Pressure Medication Recall
The affected medication is Lercanidipine HCl 20mg tablets, manufactured by Recordati Pharmaceuticals Limited. Due to a packaging error, some cartons are labeled as 10mg, while the actual tablets inside are 20mg. The discrepancy is limited to batch number MD4L07, with an expiry date of 01/2028. Notably, the correct strength is printed on the top of the carton and on the blister strips, but the side of the pack incorrectly states 10mg.
Risks from Drug Labeling Errors and Incorrect Doses
Lercanidipine is a calcium channel blocker used to treat high blood pressure. Taking a higher dose than prescribed can lead to side effects such as dizziness, palpitations, and hypotension. Therefore, patients prescribed the 10mg dosage who inadvertently take 20mg may experience these adverse effects.
MHRA Guidance: What Patients Should Do
Dr. Alison Cave, MHRA’s Chief Safety Officer, emphasized the importance of patient safety, stating, “We ask patients to check their medicine packaging and follow our advice.” The MHRA advises:
- Patients prescribed 10mg tablets: Check if your pack has batch number MD4L07. If so, contact your pharmacist or GP immediately. If you cannot reach a healthcare professional before your next dose, verify the tablet strength on the blister strip. If it’s 20mg, split the tablet in half along the break line and take half as a temporary measure.
- Patients prescribed 20mg tablets: Continue taking your medication as prescribed, ensuring the strength matches the information on the blister strip.
Pharmacy Action on Dose Confusion
Pharmacists are instructed to stop supplying medicine from the affected batch and return it to the supplier. Healthcare professionals should advise patients accordingly and report any adverse reactions via the MHRA’s Yellow Card scheme.
Reporting Side Effects and Seeking Help
Patients experiencing side effects or concerns related to this medication should report them through the MHRA’s Yellow Card scheme. This helps monitor drug safety and protect public health.
For full recall details, refer to the original article at BBC News.
Explore More : innovatemed.org
